QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 25, no. 2 (2006): 429-436
doi: 10.1377/hlthaff.25.2.429
© 2006 by Project HOPE
 
New Online
 * How Would Obama, McCain Cover The Uninsured?
 * Debating Cost Of Uninsured
 * Try Medicare-For-All
 * HA Blog Top 10
This Article
* Full Text (HTML)
* Reprint (PDF)
* Online Supplement
* Submit a response to this article
* View responses
* Alert me when this article is cited
* Alert me when eLetters are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in ISI Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via ISI Web of Science (2)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Ridley, D. B.
* Articles by Schulman, K. A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Ridley, D. B.
* Articles by Schulman, K. A.
Related Collections
* Business Of Health
* Consumer Issues
* Health Reform
* Legal/Regulatory Issues
* Pharmaceuticals
* Quality Of Care
* Research And Technology
* Health Spending

Health Tracking

MarketWatch

Spending On Postapproval Drug Safety

David B. Ridley, Judith M. Kramer, Hugh H. Tilson, Henry G. Grabowski and Kevin A. Schulman

Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding safety efforts. Mean spending on postapproval safety per company in 2003 was $56 million (0.3 percent of sales). Assuming a constant safety-to-sales ratio, we estimated that total spending on postapproval safety by the top twenty drug manufacturers was $800 million in 2003. We also examined, using regression analysis, the relationship between the number of safety personnel and the number of initial adverse-event reports. This study offers information for the debate on proposed changes to safety surveillance.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
S. D. Reed, R. M. Califf, and K. A. Schulman
How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation
Health Aff., September 1, 2006; 25(5): 1309 - 1317.
[Abstract] [Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
D. B. Ridley, H. G. Grabowski, and J. L. Moe
Developing drugs for developing countries.
Health Aff., March 1, 2006; 25(2): 313 - 324.
[Abstract] [Full Text] [PDF]

eLetters:

Read all eLetters

Of One $56M Apple and Many Uncounted Oranges: Spending on Postapproval Drug Safety
Ivo L. Abraham, et al.
Health Affairs, 28 Mar 2006 [Full text]
Reply From The Authors
David B. Ridley, et al.
Health Affairs, 6 Apr 2006 [Full text]


Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2006 Project HOPE–The People-to-People Organization
Terms and Policies